-
Mashup Score: 3
Patients with axial spondyloarthritis who receive bimekizumab demonstrate sustained improvement through 52 weeks and a safety profile consistent with shorter trials, according to data published in the Annals of the Rheumatic Diseases.“Treatment options for patients with [axial SpA (axSpA)] who have active disease despite non-steroidal anti-inflammatory drug (NSAID) treatment or who are
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis - 7 month(s) ago
Bimekizumab is now the first and only approved IL-17A and IL-17F inhibitor for this indication.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet-
🚨NEW: The US FDA has approved #bimekizumab (BIMZELX, UCB) for the treatment of adults with moderate to severe plaque #psoriasis, making it the first approved IL17-A and IL-17F inhibitor for this indication. https://t.co/r4hy401ICa
-
-
Mashup Score: 0Bimekizumab Achieved Meaningful Clinical Improvements in Hidradenitis Suppurativa, According to Data From EADV - 7 month(s) ago
UCB presented data from the BE HEARD I and BE HEARD II phase 3 studies at this year’s EADV Congress.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet-
UCB recently presented phase 3 data from its BE HEARD I and BE HEARD II phase 3 studies at this year’s EADV Congress, revealing that #bimekizumab achieved high thresholds of meaningful clinical responses in patients with #HidradenitisSuppurativa. https://t.co/PmEUcK0d3z
-
-
Mashup Score: 3
Objectives Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated superior efficacy versus placebo in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA) at Week 16. Here, the objective is to report the efficacy and safety of BKZ at Week 52. Methods BE MOBILE 1 (nr-axSpA; [NCT03928704][1]) and BE MOBILE 2 (r-axSpA; [NCT03928743][2]) comprised a 16-week, double-blind, placebo-controlled period, then a 36-week maintenance period. From Week 16, all patients received subcutaneous BKZ 160 mg every 4 weeks. Results Improvements versus placebo in Assessment of SpondyloArthritis International Society ≥40% response (primary endpoint), Ankylosing Spondylitis Disease Activity Score, high-sensitivity C-reactive protein levels and MRI inflammation of the sacroiliac joints/spine at Week 16 were sustained to Week 52 in BKZ-randomised patients. At Week 52, responses of patients switchin
Source: ard.bmj.comCategories: Latest Headlines, RheumatologyTweet-
Starting the week with two #Bimekizumab (dual IL-17A & IL-17F inhibitor) studies 1️⃣ 52-week data in #axSpA BE-MOBILE 1 (nr) & 2 (r-axSpA) ▶️ sustained efficacy across axSpA ▶️ safety profile consistent with known safety 👉 https://t.co/u2ocSycU1o @XBaraliakos @LianneGensler
-
-
Mashup Score: 0
Objectives Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with active psoriatic arthritis (PsA). Here, we report long-term efficacy and safety to Week 52. Methods BE OPTIMAL comprised a 16-week, double-blind, PBO-controlled period, then 36 weeks treatment-blind. Patients were randomised 3:2:1 to subcutaneous BKZ 160 mg every 4 weeks, PBO with switch to BKZ at Week 16, or reference arm (adalimumab (ADA) 40 mg every 2 weeks). Efficacy outcomes included the American College of Rheumatology (ACR) response criteria 20/50/70, Psoriasis Area and Severity Index (PASI) 75/90/100 in patients with baseline psoriasis affecting ≥3% body surface area and minimal disease activity (MDA); non-responder imputation. Results ACR20/50/70, PASI75/90/100 and MDA responses were sustained w
Source: ard.bmj.comCategories: Latest Headlines, RheumatologyTweet-
Starting the week with two #Bimekizumab (dual IL-17A & IL-17F inhibitor) studies 2️⃣ 52-week data in in bDMARD-naïve patients with PsA BE OPTIMAL RCT vs placebo + Adalimumab reference arm ▶️ sustained efficacy ▶️ no new safety signals 👉https://t.co/ifnf6g42uz @CRitchlin
-
-
Mashup Score: 0
Bimekizumab treatment had superior improvements in joint, skin, and radiographic efficacy outcomes at week 16 compared with placebo in patients with psoriatic arthritis who were naive to biologic DMARDs. The safety profile of bimekizumab, including the occurrence of fungal infections, was consistent with previous phase 3 studies in patients with plaque psoriasis, and with IL-17A inhibitors.
Source: The LancetCategories: Latest Headlines, RheumatologyTweet-
NEW in @TheLancet—The phase 3 BE OPTIMAL and BE COMPLETE trials of #bimekizumab (IL-17A and F) in patients with #psoriaticarthritis BE OPTIMAL > https://t.co/gObEYjRnAp BE COMPLETE > https://t.co/eTREd9Awqp Linked Comment > https://t.co/sGYWY4DBIQ https://t.co/KyEJFU7lVr
-
-
Mashup Score: 0Trial Data Suggests Bimekizumab Leads to Joint, Skin Improvements for Psoriatic Arthritis - 1 year(s) ago
New research into bimekizumab for psoriatic arthritis suggests the treatment to be effective for joint and skin improvements at 16 weeks.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
New research into #bimekizumab for #PsoriaticArthritis patients who had inadequately responded to TNFα inhibitors suggests the treatment to be effective for joint and skin improvements #psoriasis #dermatology: https://t.co/dBPHGrufac
-
-
Mashup Score: 0Bimekizumab beneficial for psoriatic arthritis in phase 3 trials - 1 year(s) ago
Bimekizumab has shown positive efficacy and safety results in the BE COMPLETE and BE OPTIMAL phase 3 psoriatic arthritis trials.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
BE COMPLETE & BE OPTIMAL trials published in @TheLancet suggest benefits of #bimekizumab in patients with #PsoriaticArthritis. Click through to read more about the studies & watch our interview with @JosephMerolaMD https://t.co/bSQkYjjfng
-
-
Mashup Score: 0
Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
And here's our interview with @PhilippeCarron, who comments on the BE COMPLETE & BE OPTIMAL findings and discusses how #bimekizumab may impact the PsA treatment landscape 👉https://t.co/JnUFgx35N5👈 https://t.co/Q9S8h8MBtN
-
-
Mashup Score: 0
PHILADELPHIA — Interleukin-17 inhibition with bimekizumab yields strong joint and skin effects up to week 52 in patients with active psoriatic arthritis, according to data presented at ACR Convergence 2022.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
ICYMI: Interleukin-17 inhibition with #bimekizumab yields strong joint and skin effects up to week 52 in patients with active psoriatic #arthritis #ACR22 #RheumTwitter #MedTwitter https://t.co/jVAcTxvHJx
-
Patients with axial spondyloarthritis who receive #bimekizumab demonstrate sustained improvement through 52 weeks and a safety profile consistent with shorter trials, said researchers @ruhrunibochum Read more 👇https://t.co/3sVkpuv90t